Loading clinical trials...
Loading clinical trials...
The primary purpose of the study is to investigate the incidence of adverse drug reactions (ADRs) (ADR of special interest: capillary leak syndrome, infusion reaction, rhabdomyolysis, myelosuppression...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Eisai Inc.
NCT06561048 · Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, and more
NCT06947967 · Lymphoma, T-Cell, Peripheral
NCT04998331 · Hodgkin Disease, Lymphoma, T-Cell, Cutaneous
NCT03789864 · Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides
NCT03742921 · Lymphoma, T-Cell, Peripheral
Eisai Trial Site 3
Nagoya
Eisai Trial Site 1
Osaka
Eisai Trial Site 2
Tokyo
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions